Pfizer CEO on Seagen Deal, Growth, Regulatory Risk

The transcript discusses the potential of new technology in combating cancer, highlighting Pfizer's interest in Cgen due to its unique technology. The partnership aims to leverage Pfizer's scale and capabilities to enhance Cgen's offerings, promising significant synergies and benefits. The deal is also seen as a strategic move to address upcoming revenue gaps due to patent expirations. Despite anticipated regulatory scrutiny, Pfizer is confident in the merger's compliance and benefits to patients.

What is the significance of the ADC mentioned in the context of cancer treatment?

How does the speaker view the potential regulatory scrutiny of the deal?

What is the anticipated timeline for the deal to close, according to the speaker?